Dear Colleague:
Thank you for registering to receive the Oncotype DX Colon Cancer On-Demand Post-ASCO GI Clinical Data Review.
This On-Demand presentation discusses the latest clinical data presented at the 2012 ASCO GI Symposium, highlighting the following:
- New perspective on risk assessment in stage II colon cancer
- QUASAR & CALGB 9581 validation studies
- Practical perspectives in using the Oncotype DX Colon Cancer Assay
- The ASCO GI abstract titled “The Effect of Oncotype DX® Colon Cancer Test Results on Treatment Recommendations in Patients with Stage II Colon Cancer”
Our ongoing commitment is to provide you with educational opportunities that help you keep pace with this evolving field. We hope you find our On-Demand series a valuable resource.
Best regards,
Calvin Chao, MD
Senior Director, Medical Affairs
Genomic Health, Inc.
This program is not endorsed by ASCO GI. American Society of Clinical Oncology and ASCO are registered trademarks of ASCO. ASCO does not endorse any product or therapy.
|
